Structure Therapeutics develops orally available small molecule drugs targeting G protein-coupled receptors (GPCRs) to provide biologic-like activity for chronic diseases such as type 2 diabetes, obesity, and pulmonary conditions. By utilizing advanced computational chemistry and structure-based technologies, the company aims to overcome the limitations of current biologic and peptide therapies.
Funding
$547.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many chronic diseases, such as type 2 diabetes, obesity, and pulmonary conditions, require treatments with biologic-like activity. Current biologic and peptide therapies face limitations in terms of delivery, stability, and cost, hindering widespread access and patient convenience.
Solution
Structure Therapeutics develops orally available small molecule drugs that target G protein-coupled receptors (GPCRs), offering a potential alternative to biologics for treating chronic diseases. The company leverages advanced computational chemistry and structure-based technologies to design molecules with high specificity and efficacy. This approach aims to overcome the limitations associated with traditional biologic and peptide drugs, providing patients with more convenient and accessible treatment options. By focusing on oral administration, Structure Therapeutics seeks to improve patient adherence and reduce healthcare costs.
Target Audience
The primary target audience includes patients with chronic diseases such as type 2 diabetes, obesity, and pulmonary conditions, as well as healthcare providers seeking more convenient and cost-effective treatment options.
Features
- Orally available small molecule drugs targeting GPCRs
- Advanced computational chemistry and structure-based drug design
- Pipeline programs for type 2 diabetes mellitus (T2DM), obesity, and pulmonary diseases
- Designed to deliver biologic-like activity and specificity